BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 28, 2026
Home » lung cancer

Articles Tagged with ''lung cancer''

Lab glassware and antibodies art concept

Crescent moon shot to scale the Summit in VEGFxPD-1

April 4, 2025
By Randy Osborne
Last October, having chalked another trial failure with E-selectin antagonist uproleselan, Glycomimetics Inc. made known its acquisition plan for privately held, solid tumor-focused Crescent Biopharma Inc. – backed by $200 million from a syndicate of investors who liked the odds of success with CR-001, a preclinical VEGFxPD-1 bispecific antibody.
Read More

More failures for TIGIT: Beigene shutters phase III lung cancer trial

April 4, 2025
By Tamra Sami
Beigene Ltd. said it is shutting down development of its anti-TIGIT antibody, ociperlimab (BGB-A1217), after the humanized IgG1-variant monoclonal antibody failed a phase III trial in lung cancer. The move is one of many in a string of anti-TIGIT immunotherapy failures.
Read More
Cancer

Mainline Biosciences discovers new peptide-drug conjugates for cancer

April 2, 2025
Mainline Biosciences (Shanghai) Co. Ltd. has described peptide-drug conjugates consisting of peptide targeting somatostatin receptors covalently bound to cytotoxic agents through a linker reported to be useful for the treatment of cancer.
Read More
Illustration of lung cancer, DNA double helix

FDA clears Gleamer, Azmed AI-powered tools for chest X-rays

April 1, 2025
By Shani Alexander
Two French startups, Gleamer SAS and Azmed SAS, received clearance from the U.S. FDA for their AI-powered tools for chest X-rays. They join an increasing number of companies developing software tools to help clinicians detect a range of abnormalities on images, enhancing diagnostic accuracy, reducing delays and improving patient outcomes.
Read More
Cancer

Filamon discovers new EGFR degradation inducers

March 31, 2025
Filamon Pty. Ltd. has described lysosomal targeting peptides (LYTAPs) acting as EGFR (HER1; erbB1) degradation inducers reported to be useful for the treatment of cancer.
Read More
mRNA on digital background
Immuno-oncology

Everest Medicines’ mRNA cancer vaccine EVM-14 gains IND clearance

March 24, 2025
Everest Medicines Ltd. has obtained IND clearance from the FDA for EVM-14, an off-the-shelf mRNA cancer vaccine targeting multiple tumor-associated antigens and designed to treat various cancers, including non-small-cell lung cancer and head and neck cancer.
Read More
Cancer

New PARG inhibitors disclosed in Forx patent

March 20, 2025
Forx Therapeutics AG has divulged poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

New TLR7 and/or TLR8 agonists disclosed in Miracure patent

March 18, 2025
Miracure Biotechnology Ltd. has divulged Toll-like receptor 7 (TLR7) and/or TLR8 agonists reported to be useful for the treatment of cancer, infections, respiratory disorders and immunological disorders.
Read More
Cancer

Wee1 inhibitors disclosed in Schroedinger patent

March 13, 2025
Schroedinger Inc. has divulged Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

New PDE4 degradation inducers disclosed in Katalytic patent

March 12, 2025
Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting moiety reported to be useful for the treatment of arthritis, Behçet’s disease, chronic obstructive pulmonary disease, non-small-cell lung cancer, inflammatory disorders, inflammatory bowel disease, psoriasis and rheumatoid arthritis.
Read More
Previous 1 2 … 14 15 16 17 18 19 20 21 22 … 50 51 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 26, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 23, 2026
  • Cortec Brain Interchange BCI system

    Brain-computer interfaces are here but long road ahead

    BioWorld
    The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
  • Illustration of red and white blood cells in an artery

    Case report links APOLD1 variant to vascular-type bleeding disorder

    BioWorld Science
    Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
  • Patient using Neuracle NEO system

    2026 marks critical turning point for BCI technology

    BioWorld
    Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing